Desvenlafaxine in the treatment of major depressive disorder

Bibliography

• Deecher DC, Beyer CE, Johnston G, Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318:657-65
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001;25:871-80
   PubMed Web of Science ®Google Scholar
• Kamath J, Handratta V. Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother 2008;8:1787-97
   PubMedGoogle Scholar
• Mason JN, Deecher DC, Richmond RL, Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther 2007;323:720-9
   PubMedGoogle Scholar
• Preskorn SH, Nichols AI, Paul J, Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract 2008;14:368-78
   PubMed Web of Science ®Google Scholar
• Nichols AI, Fatato P, Shenouda M, The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol 2009;49:219-28
   PubMed Web of Science ®Google Scholar
• Nichols AI, Focht K, Jiang Q, Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig 2011;31:155-67
   PubMed Web of Science ®Google Scholar
• Oganesian A, Shilling AD, Young-Sciame R, Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome p450 and p-glycoprotein activities. Psychopharmacol Bull 2009;42:47-63
   PubMed Web of Science ®Google Scholar
• Parker GB, Brotchie HL, Hyett M. Tolerance to desvenlafaxine in rapid metabolizing depressed patients. Int Clin Psychopharmacol 2011;26:84-7
   PubMedGoogle Scholar
• Septien-Velez L, Pitrosky B, Padmanabhan SK, A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007;22:338-47
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007;68:1663-72
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Manley AL, Padmanabhan SK, Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008;24:1877-90
   PubMed Web of Science ®Google Scholar
• Lieberman DZ, Montgomery SA, Tourian KA, A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol 2008;23:188-97
   PubMed Web of Science ®Google Scholar
• DeMartinis NA, Yeung PP, Entsuah R, A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007;68:677-88
   PubMed Web of Science ®Google Scholar
• Boyer P, Montgomery S, Lepola U, Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008;23:243-53
   PubMed Web of Science ®Google Scholar
• Feiger AD, Tourian KA, Rosas GR, A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr 2009;14:41-50
   PubMed Web of Science ®Google Scholar
• Khan A, Upton GV, Rudolph RL, The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. J Clin Psychopharmacol 1998;18:19-25
   PubMed Web of Science ®Google Scholar
• Thase ME, Kornstein SG, Germain JM, An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr 2009;14:144-54
   PubMed Web of Science ®Google Scholar
• Dunlop BW, Reddy S, Yang L, Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol 2011;31:569-76
   PubMed Web of Science ®Google Scholar
• Soares CN, Thase ME, Clayton A, Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause 2010;17:700-11
   PubMed Web of Science ®Google Scholar
• Reddy S, Kane C, Pitrosky B, Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin 2010;26:139-50
   PubMed Web of Science ®Google Scholar
• Clayton AH, Kornstein SG, Rosas G, An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr 2009;14:183-95
   PubMed Web of Science ®Google Scholar
• Speroff L, Gass M, Constantine G, Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77-87
   PubMed Web of Science ®Google Scholar
• Archer DF, Dupont CM, Constantine GD, Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009;200:238- e1-38 e10
   PubMed Web of Science ®Google Scholar
• Archer DF, Seidman L, Constantine GD, A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009;200:172- e1-10
   PubMedGoogle Scholar
• Pae CU. Desvenlafaxine: a new antidepressant or just another one? Expert Opin Pharmacother 2009;10:875-87
   PubMed Web of Science ®Google Scholar
• Nichols AI, Richards LS, Behrle JA, The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. Int J Clin Pharmacol Ther 2011;49:3-13
   PubMed Web of Science ®Google Scholar
• Cookson J, Gilaberte I, Desaiah D, Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. Int Clin Psychopharmacol 2006;21:267-73
   PubMed Web of Science ®Google Scholar
• Thase ME. Are SNRIs more effective than SSRIs? A review of the current state of the controversy. Psychopharmacol Bull 2008;41:58-85
   PubMedGoogle Scholar
• Cipriani A, Furukawa TA, Salanti G, Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58
   PubMed Web of Science ®Google Scholar
• Guico-Pabia CJ, Jiang Q, Ninan PT, Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders. Curr Med Res Opin 2011;27:1815-26
   PubMed Web of Science ®Google Scholar
• Morrow TJ. The pharmacoeconomics of venlafaxine in depression. Am J Manag Care 2001;7:S386-92
   PubMedGoogle Scholar
• Doyle JJ, Casciano J, Arikian S, A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health 2001;4:16-31
   PubMedGoogle Scholar
• Feinberg SS. Correction of venlafaxine- and duloxetine-induced transaminase elevations with desvenlafaxine in a patient with Gilbert's syndrome. CNS Spectr 2010;15:53-5
   PubMedGoogle Scholar
• Pae CU, Patkar AA. Paroxetine: current status in psychiatry. Expert Rev Neurother 2007;7:107-20
   PubMedGoogle Scholar
• Burke WJ. Selective versus multi-transmitter antidepressants: are two mechanisms better than one? J Clin Psychiatry 2004;65(Suppl 4):37-45
   PubMedGoogle Scholar